Psoriasis is a common skin condition that affects 1 in 50 people. This chronic inflammatory disease affects men and women equally and can appear at any age.
Childhood psoriasis quiz
What impact does psoriasis have on children’s well-being and how should this condition be managed? Find out with this quiz and learn more about this important topic on Medthority.
Common symptoms include itching and burning sensations, inflamed areas of skin with red patches that may crack and bleed or develop silvery-white scales. In some cases, psoriasis can affect the nails and joints as well as the skin. There are a variety of different forms that the disease can take.
Diagnosis is usually made based on the appearance and distribution of the affected patches of skin. Treatment depends upon individual circumstances. Topical treatment applied to the surface of the skin (topical corticosteroids or vitamin D analogues) is sufficient alone in most patients. For people with more extensive or difficult to treat psoriasis, ultraviolet light treatment (photo/light therapies), oral or injected treatment may be required.
Moderate to severe psoriasis is associated with an increased risk of anxiety and depression as well as a host of comorbidities. It also increases the risk of heart disease and stroke. Furthermore, it can be associated with diabetes, obesity, venous thromboembolism, high cholesterol and high blood pressure as well as inflammatory bowel disease. There is also a small increased risk of skin cancer.
To find out more, navigate through our Learning Zone where we have further information on different forms of psoriasis including inverse psoriasis, pustular psoriasis and guttate psoriasis.
Related news and insights
Novan, Inc., EPI Health, a Novan Company, and MC2 Therapeutics announced that data from a 17-question survey sponsored by the Company was published in a poster entitled, “Improving Patient Acceptability and Adherence in Psoriasis Treatment,” at the 42nd Annual Fall Clinical Dermatology Conference® taking place October 20-23, 2022, in Las Vegas, NV.
Arcutis Biotherapeutics announced positive topline results from the ARRECTOR Pivotal Phase III trial evaluating roflumilast foam 0.3%, a once-daily, non-steroidal topical phosphodiesterase-4 (PDE4) inhibitor, for the treatment of adults and adolescents with scalp and body psoriasis.
Novan, Inc. announced that EPI Health, a Novan Company, and MC2 Therapeutics presented data from a previously unpublished subgroup analysis of the U.S. Phase III pivotal study of Wynzora Cream at the Skin of Color Update 2022 Conference held September 9-11, 2022, in New York, NY
The National Advisory Committee on Immunization (NACI) provides the Public Health Agency of Canada (PHAC) with ongoing and timely medical, scientific, and public health advice relating to immunization.
On October 20, 2017, Zoster Vaccine Recombinant, Adjuvanted (Shingrix, GlaxoSmithKline, [GSK] Research Triangle Park, North Carolina), a 2-dose, subunit vaccine containing recombinant glycoprotein E in combination with a novel adjuvant (AS01B), was approved by the Food and Drug Administration for the prevention of herpes zoster in adults aged ≥50 years.